<DOC>
	<DOCNO>NCT01595087</DOCNO>
	<brief_summary>This phase I/IIa study multi-center , prospective , open-label study evaluate safety biological efficacy six dose level Osteodex patient metastatic castration resistant prostate cancer ( CRPC ) . Osteodex poly-bisphosphonate containing three know substance ; dextran , alendronate guanidine . The objective study define maximum tolerable dose Osteodex give every third week . The following objective also evaluate : overall survival , PSA response , response marker related bone metabolism ( S-ALP U-NTx ) , Quality Life assessment pharmacokinetic parameter .</brief_summary>
	<brief_title>A Phase I/II Study ODX ( Osteodex ) Metastatic Castration Resistant Prostate Cancer ( CRPC )</brief_title>
	<detailed_description>Males , diagnose CRPC , fulfil inclusion criterion exclusion criterion , ask participate study . The subject inform orally write study procedure give write informed consent , prior study start . At screen visit follow examination perform : Physical examination , medical history concomitant medication . Heart rate , blood pressure , weight , body temperature respiratory rate measure . Blood sample draw urine sample collect . ECG perform . At next visit , baseline , subject examine physically heart rate , blood pressure , weight , body temperature respiratory rate measure , ECG perform , blood sample draw urine sample collect . FACT-P questionnaire fill subject . Adverse event concomitant medication document first dose investigational product give . The subject consecutively assign dose cohort , start low dose cohort , cohort one seven cohort . Then subject survey 24 hour hospital . Prior discharge hospital examination do describe . The duration study individual subject approximately 25 week screen follow-up visit 3 week last dose . Each subject receive least 4 dos maximum 7 dos investigational product . A Data Monitoring Committee ( DMC ) designate responsible monitor/review study relate safety data . After review safety data DMC provide recommendation whether dose escalation proceed plan accord protocol .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Age ≥18 year time signing informed consent form . Histologically cytologically confirm diagnosis adenocarcinoma prostate . Failing tolerate docetaxel therapy reason suitable therapy . Evidence metastatic disease bone scan ( bone lesion ) image modality . Evidence PSA progression two consecutive determination minimum 1 week interval Castrate level serum testosterone ≤1.7 nmol/L . Performance status ECOG 02 Laboratory requirement : Haematology : Neutrophils ≥ 1.5 x 109/l Haemoglobin ≥ 90 g/l Platelets ≥ 100 x 109/l Hepatic function : Total Sbilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ( SGOT ) / ALT ( SGPT ) ≤ 2.5 time ULN Renal function : SCr ≤ 1.5 time upper limit normal ( ULN ) Electrolytes : Ssodium , Spotassium , Scalcium ( Salbumin correct ) , Sphosphate , Smagnesium , within normal range . No evidence ( ≤5 year ) prior malignancy ( except successfully treat basal cell squamous cell carcinoma skin ) Able adhere study visit schedule protocol requirement . Concurrent use anticancer agent treatment , follow exception : stable dose LHRH agonist/antagonist , polyestradiol phosphate , bicalutamide , flutamide cyproterone allow . Any treatment modality involve chemotherapy , radiation major surgery within 4 week prior treatment study . Simultaneous participation study involve investigational drug participate study le 4 week prior start study treatment . Any condition , include presence laboratory abnormality , confound ability interpret data study place patient unacceptable risk participates study . Known brain metastasis . Dental surgery ( dental extraction ) , periodontal disease , local trauma include poorly fitting denture within 6 month prior first dose study drug . Treatment bisphosphonates within 4 week prior first dose study medication .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>CRPC</keyword>
</DOC>